메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate MTS-004 has successfully met the primary endpoint in its Phase III clinical trial. MTS-004 is China's first drug candidate designed by AI-driven formulation technologies to complete Phase III development, and the first and only therapy for Pseudobulbar Affect (PBA) in the country to reach
- 김갑성 기자
- 2025-10-23 21:21
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS) — a group of bone marrow disorders characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia (AML). The FDA grants Orphan Drug Designation to the
- 김갑성 기자
- 2025-10-23 20:15
ArisGlobal Receives Frost & Sullivan's 2025 Global Intelligent MedDRA Coding New Product Innovation Recognition for AI Leadership and Customer Impact

[ 메디채널 김갑성 기자 ] ArisGlobal is honored for its technological breakthrough in intelligent MedDRA coding that enhances accuracy, accelerates compliance workflows, and advances innovation in pharmacovigilance. SAN ANTONIO, Oct. 23, 2025 -- Frost & Sullivan is pleased to announce that ArisGlobal has received the 2025 Global New Product Innovation Recognition in the intelligent MedDRA Coding industry for its outstanding achievements in innovation, customer impact, and market leadership. This recognition highlights ArisGlobal's consistent leadership in developing technology solutions th
- 김갑성 기자
- 2025-10-23 20:05
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM) that, for the first time, include the use of Telix's investigational PET[1] agent, TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), for molecular imaging of renal masses. Published on the SNMMI website[3] and in The Journal of Nucl
- 김갑성 기자
- 2025-10-23 19:00
Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific

With a strong track record across APAC, Francis Wan's appointment marks a powerful acceleration of Medison's growth in the region ZUG, Switzerland, Oct. 23, 2025 -- Medison, the creator of a first-of-its-kind unified global commercialization platform for breakthrough therapies, today announced the appointment of Francis Wan as VP, GM Asia Pacific (APAC) and member of the company's Global Leadership Team. Francis will lead Medison's strategy and operations across the APAC region, a critical growth area for the company's platform. With more than 20 years of biopha
- 김갑성 기자
- 2025-10-23 19:00
HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology

[ 메디채널 김갑성 기자 ] Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hem
- 김갑성 기자
- 2025-10-23 19:00
BTL의 EMSCULPT NEO, 국제 우주 임무를 수행할 헝가리 우주비행사 훈련에 활용

프라하, 2025년 10월 21일 -- 의료기술 분야의 글로벌 리더 BTL이 자사의 주력 의료기기 제품인 EMSCULPT NEO가 역사적인 우주 비행을 앞둔 우주비행사의 준비 과정에서 핵심적인 역할을 수행했다고 발표했다. HUNOR(Hungarian To Orbit) 프로그램은 BTL 헝가리와 손잡고 헝가리 연구 우주비행사 티보르 카푸(Tibor Kapu)의 국제우주정거장(ISS) 탑승 임무를 위한 비행 전 집중 훈련 프로그램에 EMSCULPT NEO를 도입했다. 우주비행사 훈련팀을 이끈 부다페스트 세멜바이스 대학의 심장 전문의이자 스포츠 의학 전문가인 노라 사이도(Nóra Sydó) 박사는 "연구에 따르면 우주비행사들은 임무 기간에 따라 궤도상에서 최대 30%의 근육량을 잃게 된다"면서 "EMSCULPT NEO는 근육 성능과 회복을 극대화하는 데 도움을 주면서 신체 훈련과 재활에 필수적인 역할을 했다"고 말했다. EMSCULPT NEO는 지구력, 근력, 균형감, 회복력을 향상시키기 위해 고안된 종합 훈련 계획의 일부였다. 헝가리 올림픽 수영
- 김갑성 기자
- 2025-10-23 15:06
International Youth Explore the Wisdom of Traditional Chinese Medicine Zhangshu National Pharma Fair Opens a New Chapter in Cultural Experience

ZHANGSHU, China, Oct. 23, 2025 -- A report from Jiangxi International Communication Center (JXICC): "Without Zhangshu, medicines are incomplete; without Zhangshu, medicines lack efficacy." On October 16, 2025, Jiangxi's Zhangshu Qihuang Town was bustling with crowds as the 56th National Medicinal Materials and Pharmaceuticals Trade Fair grandly opened here. Simultaneously, an international youth exploration journey in Jiangxi, themed "From Ancient Wisdom to Modern Wellness," was launched. This event was jointly organized by the Jiangxi International Communication Center an
- 김갑성 기자
- 2025-10-23 14:46
1doc Academy and Kingston International College Partner to Strengthen Singapore's Healthcare Workforce through Applied Learning and Digital Innovation

SINGAPORE, Oct. 23, 2025 -- 1doc Academy, the training arm of iAPPS Health Group (1doc) and Kingston International College (KIC) formalised their partnership with the signing of an agreement at GovWare 2025 on 22 October. The ceremony was witnessed by Senior Minister of State Tan Kiat How, Ministry of Health and Ministry of Digital Development and Information. The agreement marks the launch of a strategic collaboration to co-develop and deliver a comprehensive education and training pathway for future healthcare professionals. The launch of Healthier SG marks a pivotal shift in
- 김갑성 기자
- 2025-10-23 14:34
MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring

SÃO PAULO, Oct. 23, 2025 -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing essential tools and technologies to drive innovation in the life sciences, has entered into a strategic partnership with Eva Holding Group, a Brazilian group operating in genomics applied to human health, animal health, and agribusiness. The initiative aims to expand Brazilian patients' access to genomics, including joint efforts in the development of the country's genetic sector. The agreement includes the installation of genetic sequencers that expand public acce
- 김갑성 기자
- 2025-10-23 11:30

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 14시 40분